The Thai VaxGen Trial: What Have We learned?
Chris Beyrer
from: AIDS Vaccine Development: Challenges and Opportunities (Edited by: Wayne Koff, Patricia Kahn and Ian D. Gust). Caister Academic Press, U.K. (2007)
Abstract
One year after VaxGen launched its Phase III vaccine trial in 5,000 North Americans and Europeans at risk for sexual transmission of HIV (Chapter 14), a second trial began in 2,500 intravenous drug users in Thailand. In November 2003, analysis of final results from the Thai trial showed clearly that the gp120-based AIDSVAX vaccine had no efficacy in this population, in agreement with results from the first Phase III study. Despite these disappointing findings, the trial yielded invaluable information about conducting large-scale studies in IDU populations-something many researchers thought could not be done-and offers compelling insights into the conduct of future efficacy trials in developing countries read more ...
